Search

Your search keyword '"TREVISANI, FRANCO"' showing total 1,157 results
Start Over Author "TREVISANI, FRANCO"
1,157 results on '"TREVISANI, FRANCO"'

1. Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib

Author

Stefanini, Bernardo, Tovoli, Francesco, Trevisani, Franco, Marseglia, Mariarosaria, Di Costanzo, Giovan Giuseppe, Cabibbo, Giuseppe, Sacco, Rodolfo, Pellizzaro, Filippo, Pressiani, Tiziana, Chen, Rusi, Ponziani, Francesca Romana, Foschi, Francesco Giuseppe, Magini, Giulia, Granito, Alessandro, and Piscaglia, Fabio

Published
2024
Full Text
View/download PDF

2. Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care

Author

Stefanini, Benedetta, Bucci, Laura, Santi, Valentina, Reggidori, Nicola, Lani, Lorenzo, Granito, Alessandro, Pelizzaro, Filippo, Cabibbo, Giuseppe, Di Marco, Mariella, Ghittoni, Giorgia, Campani, Claudia, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Giannini, Edoardo G., Biasini, Elisabetta, Saitta, Carlo, Magalotti, Donatella, Sangiovanni, Angelo, Guarino, Maria, Gasbarrini, Antonio, Rapaccini, Gian Ludovico, Masotto, Alberto, Sacco, Rodolfo, Vidili, Gianpaolo, Mega, Andrea, Azzaroli, Francesco, Nardone, Gerardo, Brandi, Giovanni, Sabbioni, Simone, Vitale, Alessandro, and Trevisani, Franco

Published
2024
Full Text
View/download PDF

4. Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part II – Non-surgical treatments

Author

Cabibbo, Giuseppe, Daniele, Bruno, Borzio, Mauro, Casadei-Gardini, Andrea, Cillo, Umberto, Colli, Agostino, Conforti, Massimiliano, Dadduzio, Vincenzo, Dionisi, Francesco, Farinati, Fabio, Gardini, Ivan, Giannini, Edoardo Giovanni, Golfieri, Rita, Guido, Maria, Mega, Andrea, Cinquini, Michela, Piscaglia, Fabio, Rimassa, Lorenza, Romanini, Laura, Pecorelli, Anna, Sacco, Rodolfo, Scorsetti, Marta, Viganò, Luca, Vitale, Alessandro, and Trevisani, Franco

Published
2024
Full Text
View/download PDF

5. Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part I – Surgical treatments

Author

Cabibbo, Giuseppe, Daniele, Bruno, Borzio, Mauro, Casadei-Gardini, Andrea, Cillo, Umberto, Colli, Agostino, Conforti, Massimiliano, Dadduzio, Vincenzo, Dionisi, Francesco, Farinati, Fabio, Gardini, Ivan, Giannini, Edoardo Giovanni, Golfieri, Rita, Guido, Maria, Mega, Andrea, Minozzi, Silvia, Piscaglia, Fabio, Rimassa, Lorenza, Romanini, Laura, Pecorelli, Anna, Sacco, Rodolfo, Scorsetti, Marta, Viganò, Luca, Vitale, Alessandro, and Trevisani, Franco

Published
2024
Full Text
View/download PDF

6. Impact of a newly established expert clinical pharmacological advice programme based on therapeutic drug monitoring results in tailoring antimicrobial therapy hospital-wide in a tertiary university hospital: Findings after the first year of implementation

Author

Cojutti, Pier Giorgio, Gatti, Milo, Bonifazi, Francesca, Caramelli, Fabio, Castelli, Andrea, Cavo, Michele, Cescon, Matteo, Corvaglia, Luigi Tommaso, Lanari, Marcello, Marinelli, Sara, Morelli, Maria Cristina, Pession, Andrea, Poggioli, Gilberto, Ramirez, Stefania, Siniscalchi, Antonio, Tonetti, Tommaso, Trevisani, Franco, Zanoni, Andrea, Zinzani, Pier Luigi, Gibertoni, Chiara, Viale, Pierluigi, and Pea, Federico

Published
2023
Full Text
View/download PDF

7. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs

Author

Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Benevento, Francesca, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Tovoli, Francesco, Allegrini, Gloria, Cammà, Calogero, Cabibbo, Giuseppe, Giacchetto, Carmelo Marco, Giuffrida, Paolo, Grassini, Maria Vittoria, Grova, Mauro, Rancatore, Gabriele, Stornello, Caterina, Adotti, Valentina, Cavoli, Tancredi Li, Marra, Fabio, Rosi, Martina, Bevilacqua, Vittoria, Borghi, Alberto, Napoli, Lucia, Conti, Fabio, Frassineti, G.L., Migliano, Maria Teresa, de Matthaeis, Nicoletta, Ponziani, Francesca Romana, Missale, Gabriele, Olivani, Andrea, Capasso, Mario, Cossiga, Valentina, Guarino, Maria, Marina Cela, Ester, Facciorusso, Antonio, Graziosi, Camilla, Lauria, Valentina, Pelecca, Giorgio, Schirripa, Marta, Chegai, Fabrizio, Raso, Armando, Bozzi, Alessio, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Dajti, Elton, Ravaioli, Federico, Plaz Torres, Maria Corina, Pieri, Giulia, Oliveri, Filippo, Ricco, Gabriele, Romagnoli, Veronica, Inno, Alessandro, Marchetti, Fabiana, Coccoli, Pietro, Malerba, Antonio, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Reggidori, Nicola, Bucci, Laura, Santi, Valentina, Stefanini, Benedetta, Lani, Lorenzo, Rampoldi, Davide, Ghittoni, Giorgia, Farinati, Fabio, Masotto, Alberto, Stefanini, Bernardo, Mega, Andrea, Biasini, Elisabetta, Foschi, Francesco Giuseppe, Svegliati-Baroni, Gianluca, Sangiovanni, Angelo, Campani, Claudia, Raimondo, Giovanni, Vidili, Gianpaolo, Gasbarrini, Antonio, Celsa, Ciro, Di Marco, Mariella, Giannini, Edoardo G., Sacco, Rodolfo, Brunetto, Maurizia Rossana, Azzaroli, Francesco, Magalotti, Donatella, Morisco, Filomena, Rapaccini, Gian Ludovico, Nardone, Gerardo, Vitale, Alessandro, and Trevisani, Franco

Published
2023
Full Text
View/download PDF

8. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept

Author

Baccarani, Umberto, Brancaccio, Giuseppina, Cozzolongo, Raffaele, Cucchetti, Alessandro, De Matthaeis, Nicoletta, Di Sandro, Stefano, Famularo, Simone, Finotti, Michele, Foschi, Francesco G, Ghinolfi, Davide, Guarracino, Marco, Gruttadauria, Salvatore, Guarino, Maria, Kostandini, Alba, Lenci, Ilaria, Levi Sandri, Giovanni B, Manzia, Tommaso M, Marasco, Giovanni, Masarone, Mario, Mazzarelli, Chiara, Melandro, Fabio, Miele, Luca, Morisco, Filomena, Nicolini, Daniele, Pagano, Duilio, Pelizzaro, Filippo, Pieri, Giulia, Piscaglia, Fabio, Plaz Torres, Maria Corina, Pravisani, Riccardo, Rendina, Maria, Romano, Fabrizio, Russo, Francesco P, Sacco, Rodolfo, Sangiovanni, Angelo, Sposito, Carlo, Tortora, Raffaella, Tovoli, Francesco, Viganò, Mauro, Violi, Paola, Vitale, Alessandro, Cabibbo, Giuseppe, Iavarone, Massimo, Viganò, Luca, Pinato, David J, Ponziani, Francesca Romana, Lai, Quirino, Casadei-Gardini, Andrea, Celsa, Ciro, Galati, Giovanni, Gambato, Martina, Crocetti, Laura, Renzulli, Matteo, Giannini, Edoardo G, Farinati, Fabio, Trevisani, Franco, and Cillo, Umberto

Published
2023
Full Text
View/download PDF

12. SAT-477-YI The impact of etiologyon patterns of progression of advanced HCC

Author

Stefanini, Bernardo, primary, Piscaglia, Fabio, additional, Dalbeni, Andrea, additional, Vivaldi, Caterina, additional, Federico, Piera, additional, Palloni, Andrea, additional, Soldà, Caterina, additional, Stefanini, Benedetta, additional, Garajova, Ingrid, additional, Ielasi, Luca, additional, De Lorenzo, Stefania, additional, Masi, Gianluca, additional, Lonardi, Sara, additional, Brandi, Giovanni, additional, Daniele, Bruno, additional, Trevisani, Franco, additional, Svegliati-Baroni, Gianluca, additional, Campani, Claudia, additional, Chen, Rusi, additional, and Tovoli, Francesco, additional

Published
2024
Full Text
View/download PDF

14. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma

Author

Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Benevento, Francesca, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Bertellini, Federica, Farinati, Fabio, Palano, Giorgio, Pelizzaro, Filippo, Penzo, Barbara, Pinto, Elisa, Allegrini, Gloria, Cammà, Calogero, Celsa, Ciro, Giuffrida, Paolo, Stornello, Caterina, Grova, Mauro, Giacchetto, Carmelo Marco, Rancatore, Gabriele, Grassini, Maria Vittoria, Adotti, Valentina, Gitto, Stefano, Marra, Fabio, Rosi, Martina, Bevilacqua, Vittoria, Borghi, Alberto, Gardini, Andrea Casadei, Conti, Fabio, Napoli, Lucia, Domenicali, Marco, Migliano, Maria Teresa, de Matthaeis, Nicoletta, Ponziani, Francesca Romana, Olivani, Andrea, Missale, Gabriele, Cossiga, Valentina, Capasso, Mario, Morisco, Filomena, Cela, Ester Marina, Facciorusso, Antonio, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Dell'Isola, Serena, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Dajti, Elton, Ravaioli, Federico, Oliveri, Filippo, Ricco, Gabriele, Romagnoli, Veronica, Inno, Alessandro, Marchetti, Fabiana, Coccoli, Pietro, Malerba, Antonio, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Giannini, Edoardo G., Pieri, Giulia, Labanca, Sara, Plaz Torres, Maria Corina, Gasbarrini, Antonio, Biasini, Elisabetta, Campani, Claudia, Cazzagon, Nora, Foschi, Francesco Giuseppe, Mega, Andrea, Masotto, Alberto, Raimondo, Giovanni, Rapaccini, Gian Ludovico, Sacco, Rodolfo, Caturelli, Eugenio, Guarino, Maria, Tovoli, Francesco, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Nardone, Gerardo, Svegliati-Baroni, Gianluca, Magalotti, Donatella, Azzaroli, Francesco, Cabibbo, Giuseppe, Di Marco, Maria, Sangiovanni, Angelo, and Trevisani, Franco

Published
2022
Full Text
View/download PDF

17. Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib

Author

Biselli, Maurizio, primary, Reggidori, Nicola, additional, Iavarone, Massimo, additional, Renzulli, Matteo, additional, Lani, Lorenzo, additional, Granito, Alessandro, additional, Piscaglia, Fabio, additional, Lorenzini, Stefania, additional, Alimenti, Eleonora, additional, Vara, Giulio, additional, Caraceni, Paolo, additional, Sangiovanni, Angelo, additional, Marignani, Massimo, additional, Gigante, Elia, additional, Brandi, Nicolò, additional, Gramenzi, Annagiulia, additional, and Trevisani, Franco, additional

Published
2024
Full Text
View/download PDF

19. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.

Author

Marasco, Giovanni, Colecchia, Antonio, Bacchi Reggiani, Maria Letizia, Celsa, Ciro, Farinati, Fabio, Giannini, Edoardo Giovanni, Benevento, Francesca, Rapaccini, Gian Ludovico, Caturelli, Eugenio, Di Marco, Mariella, Biasini, Elisabetta, Marra, Fabio, Morisco, Filomena, Foschi, Francesco Giuseppe, Zoli, Marco, Gasbarrini, Antonio, Baroni, Gianluca Svegliati, Masotto, Alberto, Sacco, Rodolfo, Raimondo, Giovanni, Azzaroli, Francesco, Mega, Andrea, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Nardone, Gerardo, Dajti, Elton, Ravaioli, Federico, Avanzato, Francesca, Festi, Davide, and Trevisani, Franco

Published
2021
Full Text
View/download PDF

20. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction

Author

Fulgenzi, Claudia Angela Maria, Scheiner, Bernhard, D’Alessio, Antonio, Mehan, Aman, Manfredi, Giulia F., Celsa, Ciro, Nishida, Naoshi, Ang, Celina, Marron, Thomas U., Wu, Linda, Saeed, Anwaar, Wietharn, Brooke, Cammarota, Antonella, Pressiani, Tiziana, Pinter, Matthias, Sharma, Rohini, Cheon, Jaekyung, Huang, Yi-Hsiang, Lee, Pei-Chang, Phen, Samuel, Gampa, Anuhya, Pillai, Anjana, Napolitano, Andrea, Vivaldi, Caterina, Salani, Francesca, Masi, Gianluca, Silletta, Marianna, Lo Prinzi, Federica, Di Giacomo, Emanuela, Vincenzi, Bruno, Bettinger, Dominik, Thimme, Robert, Vogel, Arndt, Schönlein, Martin, von Felden, Johann, Schulze, Kornelius, Wege, Henning, Galle, Peter R., Pirisi, Mario, Park, Joong-Won, Kudo, Masatoshi, Rimassa, Lorenza, Singal, Amit G., El Tomb, Paul, Ulahannan, Susanna, Parisi, Alessandro, Chon, Hong Jae, Hsu, Wei-Fan, Ghittoni, Giorgia, Cammà, Calogero, Stefanini, Benedetta, Trevisani, Franco, Giannini, Edoardo G., Cortellini, Alessio, and Pinato, David James

Abstract

IMPORTANCE: Whether patients with Child-Pugh class B (CP-B) cancer with unresectable hepatocellular carcinoma (uHCC) benefit from active anticancer treatment vs best supportive care (BSC) is debated. OBJECTIVE: To evaluate the association of immune checkpoint inhibitor (ICI)–based therapies vs BSC with overall survival (OS) of patients with uHCC and CP-B liver dysfunction. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, multicenter, international clinical case series examined data of patients with CP-B with uHCC who were receiving first-line ICI-based regimens from September 2017 to December 2022 whose data were extracted from an international consortium and compared with a cohort of patients with CP-B receiving BSC. Patients were treated in tertiary care centers across Europe, US, and Asia in routine clinical practice. After applying the inclusion criteria, 187 and 156 patients were left in the ICI and BSC groups, respectively. The propensity score was calculated for the following variables: age, alpha-fetoprotein levels, Child-Pugh score, extrahepatic spread, portal vein tumor thrombosis, cirrhosis, ascites, and baseline Eastern Cooperative Oncology Group performance status. EXPOSURES: Patients in the ICI group received first-line systemic therapy with either atezolizumab plus bevacizumab (A+B) (n = 141) or nivolumab (n = 46). MAIN OUTCOMES AND MEASURES: OS in the inverse probability of treatment weighting (IPTW) populations was the main outcome, and it was estimated with Kaplan-Meier method; univariable Cox regression test was used to make comparisons between the 2 groups. RESULTS: The median age was 66 (IQR, 61-72) and 73 (IQR, 66-81) years in the ICI (33 women [18%]) and BSC groups (41 women [26%]), respectively. In the IPTW populations, median OS was significantly longer in the ICI group (7.50 months; 95% CI, 5.62-11.15) compared with BSC (4.04 months; 95% CI, 3.03-5.03; hazard ratio, 0.59; 95% CI, 0.43-0.80; P < .001). Multivariable analysis confirmed that ICI exposure was associated with a reduction of approximately 50% in the risk of death (hazard ratio, 0.55; 95% CI, 0.35-0.86; P < .001), and the presence of portal vein tumor thrombosis, an Eastern Cooperative Oncology Group performance score of greater than 1, and alpha-fetoprotein levels of 400 ng/mL or greater were associated with increased risk of death. CONCLUSIONS AND RELEVANCE: The results of this case series provide comparative evidence of improved survival in association with ICI treatment compared with BSC in patients with uHCC with CP-B liver dysfunction.

Published
2024
Full Text
View/download PDF

21. Liver Resection vs Nonsurgical Treatments for Patients With Early Multinodular Hepatocellular Carcinoma.

Author

Vitale, Alessandro, Romano, Pierluigi, Cillo, Umberto, Lauterio, Andrea, Sangiovanni, Angelo, Cabibbo, Giuseppe, Missale, Gabriele, Marseglia, Mariarosaria, Trevisani, Franco, Foschi, Francesco Giuseppe, Cipriani, Federica, Famularo, Simone, Marra, Fabio, Saitta, Carlo, Serenari, Matteo, Vidili, Gianpaolo, Morisco, Filomena, Caturelli, Eugenio, Mega, Andrea, and Pelizzaro, Filippo

Published
2024
Full Text
View/download PDF

22. Surveillance for Hepatocellular Carcinoma in Patients with Successfully Treated Viral Disease of the Liver: A Systematic Review.

Author

Lani, Lorenzo, Stefanini, Benedetta, and Trevisani, Franco

Subjects
DISEASE risk factors, HEPATITIS C virus, HEPATITIS B virus, VIRAL hepatitis, CHRONIC active hepatitis, HEPATITIS C
Abstract

Background: Surveillance for hepatocellular carcinoma (HCC) has been proven to increase the proportion of tumors detected at early stages and the chance of receiving curative therapies, reducing mortality by about 30%. Summary: Current recommendations consist of a semi-annual abdominal ultrasound with or without serum alpha-fetoprotein measurement in patients with cirrhosis and specific subgroups of populations with chronic viral hepatitis. Antiviral therapies, such as nucleot(s)ide analogs that efficiently suppress the replication of hepatitis B virus (HBV) and direct-acting antiviral drugs able to eliminate the hepatitis C virus (HCV) in >90% of patients, have radically changed the outcomes of viral liver disease and decreased, but not eliminated, the risk of HCC in both cirrhotic and non-cirrhotic patients. HCC risk is a key starting point for implementing a cost-effective surveillance and should also guide the decision-making process concerning its modality. As the global number of effectively treated viral patients continues to rise, there is a pressing need to identify those for whom the benefit-to-harm ratio of surveillance is favorable and to determine how to conduct cost-effective screening on such patients. Key Messages: This article addresses this topic and attempts to determine which patients should continue HCC surveillance after HBV suppression or HCV eradication, based on cost-effectiveness principles and the fact that HCC risk declines over time. We also formulate a proposal for a surveillance algorithm that switches the use of surveillance for HCC from the "one-size-fits-all" approach to individualized programs based on oncologic risk (precision surveillance). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Sport and Gender

Author

Trevisani, Franco, Villa, Francesco Della, Tarricone, Ilaria, editor, and Riecher-Rössler, Anita, editor

Published
2019
Full Text
View/download PDF

25. Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy

Author

Ielasi, Luca, primary, Stefanini, Bernardo, additional, Conti, Fabio, additional, Tonnini, Matteo, additional, Tortora, Raffaella, additional, Magini, Giulia, additional, Sacco, Rodolfo, additional, Pressiani, Tiziana, additional, Trevisani, Franco, additional, Foschi, Francesco Giuseppe, additional, Piscaglia, Fabio, additional, Granito, Alessandro, additional, and Tovoli, Francesco, additional

Published
2024
Full Text
View/download PDF

29. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

Author

Cabibbo, Giuseppe, Celsa, Ciro, Calvaruso, Vincenza, Petta, Salvatore, Cacciola, Irene, Cannavò, Maria Rita, Madonia, Salvatore, Rossi, Margherita, Magro, Bianca, Rini, Francesca, Distefano, Marco, Larocca, Licia, Prestileo, Tullio, Malizia, Giuseppe, Bertino, Gaetano, Benanti, Francesco, Licata, Anna, Scalisi, Ignazio, Mazzola, Giovanni, Di Rosolini, Maria Antonietta, Alaimo, Giuseppe, Averna, Alfonso, Cartabellotta, Fabio, Alessi, Nicola, Guastella, Salvatore, Russello, Maurizio, Scifo, Gaetano, Squadrito, Giovanni, Raimondo, Giovanni, Trevisani, Franco, Craxì, Antonio, Di Marco, Vito, and Cammà, Calogero

Published
2019
Full Text
View/download PDF

30. Development and Validation of a Scoring System That Includes Corrected QT Interval for Risk Analysis of Patients With Cirrhosis and Gastrointestinal Bleeding

Author

Biselli, Maurizio, Gramenzi, Annagiulia, Lenzi, Barbara, Dall’Agata, Marco, Pierro, Monica Loreta, Perricone, Giovanni, Tonon, Marta, Bellettato, Luca, D’Amico, Gennaro, Angeli, Paolo, Boffelli, Silvia, Bonavita, Maria Elena, Domenicali, Marco, Caraceni, Paolo, Bernardi, Mauro, and Trevisani, Franco

Published
2019
Full Text
View/download PDF

31. Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part I – Surgical treatments

Author

Cabibbo, Giuseppe, primary, Daniele, Bruno, additional, Borzio, Mauro, additional, Casadei-Gardini, Andrea, additional, Cillo, Umberto, additional, Colli, Agostino, additional, Conforti, Massimiliano, additional, Dadduzio, Vincenzo, additional, Dionisi, Francesco, additional, Farinati, Fabio, additional, Gardini, Ivan, additional, Giannini, Edoardo Giovanni, additional, Golfieri, Rita, additional, Guido, Maria, additional, Mega, Andrea, additional, Minozzi, Silvia, additional, Piscaglia, Fabio, additional, Rimassa, Lorenza, additional, Romanini, Laura, additional, Pecorelli, Anna, additional, Sacco, Rodolfo, additional, Scorsetti, Marta, additional, Viganò, Luca, additional, Vitale, Alessandro, additional, and Trevisani, Franco, additional

Published
2023
Full Text
View/download PDF

34. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs

Author

Reggidori, Nicola, primary, Bucci, Laura, additional, Santi, Valentina, additional, Stefanini, Benedetta, additional, Lani, Lorenzo, additional, Rampoldi, Davide, additional, Ghittoni, Giorgia, additional, Farinati, Fabio, additional, Masotto, Alberto, additional, Stefanini, Bernardo, additional, Mega, Andrea, additional, Biasini, Elisabetta, additional, Foschi, Francesco Giuseppe, additional, Svegliati-Baroni, Gianluca, additional, Sangiovanni, Angelo, additional, Campani, Claudia, additional, Raimondo, Giovanni, additional, Vidili, Gianpaolo, additional, Gasbarrini, Antonio, additional, Celsa, Ciro, additional, Di Marco, Mariella, additional, Giannini, Edoardo G., additional, Sacco, Rodolfo, additional, Brunetto, Maurizia Rossana, additional, Azzaroli, Francesco, additional, Magalotti, Donatella, additional, Morisco, Filomena, additional, Rapaccini, Gian Ludovico, additional, Nardone, Gerardo, additional, Vitale, Alessandro, additional, Trevisani, Franco, additional, Biselli, Maurizio, additional, Caraceni, Paolo, additional, Gramenzi, Annagiulia, additional, Benevento, Francesca, additional, Granito, Alessandro, additional, Muratori, Luca, additional, Piscaglia, Fabio, additional, Tovoli, Francesco, additional, Allegrini, Gloria, additional, Cammà, Calogero, additional, Cabibbo, Giuseppe, additional, Giacchetto, Carmelo Marco, additional, Giuffrida, Paolo, additional, Grassini, Maria Vittoria, additional, Grova, Mauro, additional, Rancatore, Gabriele, additional, Stornello, Caterina, additional, Adotti, Valentina, additional, Cavoli, Tancredi Li, additional, Marra, Fabio, additional, Rosi, Martina, additional, Bevilacqua, Vittoria, additional, Borghi, Alberto, additional, Napoli, Lucia, additional, Conti, Fabio, additional, Frassineti, G.L., additional, Migliano, Maria Teresa, additional, de Matthaeis, Nicoletta, additional, Ponziani, Francesca Romana, additional, Missale, Gabriele, additional, Olivani, Andrea, additional, Capasso, Mario, additional, Cossiga, Valentina, additional, Guarino, Maria, additional, Marina Cela, Ester, additional, Facciorusso, Antonio, additional, Graziosi, Camilla, additional, Lauria, Valentina, additional, Pelecca, Giorgio, additional, Schirripa, Marta, additional, Chegai, Fabrizio, additional, Raso, Armando, additional, Bozzi, Alessio, additional, Franzè, Maria Stella, additional, Saitta, Carlo, additional, Sauchella, Assunta, additional, Dajti, Elton, additional, Ravaioli, Federico, additional, Plaz Torres, Maria Corina, additional, Pieri, Giulia, additional, Oliveri, Filippo, additional, Ricco, Gabriele, additional, Romagnoli, Veronica, additional, Inno, Alessandro, additional, Marchetti, Fabiana, additional, Coccoli, Pietro, additional, Malerba, Antonio, additional, Cappelli, Alberta, additional, Golfieri, Rita, additional, Mosconi, Cristina, additional, and Renzulli, Matteo, additional

Published
2023
Full Text
View/download PDF

37. Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunction

Author

Fulgenzi, Claudia, primary, D’Alessio, Antonio, additional, Scheiner, Bernhard, additional, Nishida, Naoshi, additional, Ang, Celina, additional, Marron, Thomas, additional, Wu, Linda, additional, Saeed, Anwaar, additional, Wietharn, Brooke, additional, Cammarota, Antonella, additional, Pressiani, Tiziana, additional, Pinter, Matthias, additional, Sharma, Rohini, additional, Cheon, Jaekyung, additional, Huang, Yi-Hsiang, additional, Lee, Pei-Chang, additional, Phen, Samuel, additional, Gampa, Anuhya, additional, Pillai, Anjana, additional, Napolitano, Andrea, additional, Vivaldi, Caterina, additional, Salani, Francesca, additional, Masi, Gianluca, additional, Bettinger, Dominik, additional, Thimme, Robert, additional, Vogel, Arndt, additional, Schoenlein, Martin, additional, Schulze, Kornelius, additional, von Felden, Johann, additional, Wege, Henning, additional, Galle, Peter, additional, Pirisi, Mario, additional, Park, Joong-Won, additional, Kudo, Masatoshi, additional, Rimassa, Lorenza, additional, Singal, Amit, additional, Cortellini, Alessio, additional, Chon, Hong Jae, additional, Ghittoni, Giorgia, additional, Camma, Calogero, additional, Stefanini, Benedetta, additional, Trevisani, Franco, additional, Giannini, Edoardo Giovanni, additional, and Pinato, David J., additional

Published
2023
Full Text
View/download PDF

38. Prognostic impact of metastatic site in patients receiving first-line sorafenib therapy for advanced hepatocellular carcinoma

Author

Lelasi, Luca, primary, Tovoli, Francesco, additional, Tonnini, Matteo, additional, Stefanini, Bernardo, additional, Tortora, Raffaella, additional, Magini, Giulia, additional, Sacco, Rodolfo, additional, Pressiani, Tiziana, additional, Trevisani, Franco, additional, Piscaglia, Fabio, additional, and Granito, Alessandro, additional

Published
2023
Full Text
View/download PDF

41. Predictors of non‐transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection.

Author

Pelizzaro, Filippo, Trevisani, Franco, Simeon, Vittorio, Vitale, Alessandro, Cillo, Umberto, Piscaglia, Fabio, Missale, Gabriele, Sangiovanni, Angelo, Foschi, Francesco G., Cabibbo, Giuseppe, Caturelli, Eugenio, Di Marco, Maria, Azzaroli, Francesco, Brunetto, Maurizia R., Raimondo, Giovanni, Vidili, Gianpaolo, Guarino, Maria, Gasbarrini, Antonio, Campani, Claudia, and Svegliati‐Baroni, Gianluca

Subjects
*LIVER cancer, *LIVER, *OVERALL survival, *DISEASE relapse, *DATABASES
Abstract

Background and Aims: Hepatocellular carcinoma (HCC) recurrence is common in patients treated with liver resection (LR). In this study, we aimed to evaluate the incidence and preoperative predictors of non‐transplantable recurrence in patients with single HCC ≤5 cm treated with frontline LR. Methods: From the Italian Liver Cancer (ITA.LI.CA) database, 512 patients receiving frontline LR for single HCC ≤5 cm were retrieved. Incidence and predictors of recurrence beyond Milan criteria (MC) and up‐to‐seven criteria were compared between patients with HCC <4 and ≥4 cm. Results: During a median follow‐up of 4.2 years, the overall recurrence rate was 55.9%. In the ≥4 cm group, a significantly higher proportion of patients recurred beyond MC at first recurrence (28.9% vs. 14.1%; p < 0.001) and overall (44.4% vs. 25.2%; p < 0.001). Similar results were found considering recurrence beyond up‐to‐seven criteria. Compared to those with larger tumours, patients with HCC <4 cm had a longer recurrence‐free survival and overall survival. HCC size ≥4 cm and high alpha‐fetoprotein (AFP) level at the time of LR were independent predictors of recurrence beyond MC (and up‐to‐seven criteria). In the subgroup of patients with available histologic information (n = 354), microvascular invasion and microsatellite lesions were identified as additional independent risk factors for non‐transplantable recurrence. Conclusions: Despite the high recurrence rate, LR for single HCC ≤5 cm offers excellent long‐term survival. Non‐transplantable recurrence is predicted by HCC size and AFP levels, among pre‐operatively available variables. High‐risk patients could be considered for frontline LT or listed for transplantation even before recurrence. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

42. Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group

Author

Vitale, Alessandro, Lai, Quirino, Farinati, Fabio, Bucci, Laura, Giannini, Edoardo G., Napoli, Lucia, Ciccarese, Francesca, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Sacco, Rodolfo, Cabibbo, Giuseppe, Virdone, Roberto, Marra, Fabio, Felder, Martina, Morisco, Filomena, Benvegnù, Luisa, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Colecchia, Antonio, Bernardi, Mauro, Trevisani, Franco, Pawlik, Timothy M., and On behalf of the Italian Liver Cancer (ITA.LI.CA) group

Published
2018
Full Text
View/download PDF

45. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept

Author

Vitale, Alessandro, Cabibbo, Giuseppe, Iavarone, Massimo, Viganò, Luca, Pinato, David J, Ponziani, Francesca Romana, Lai, Quirino, Casadei-Gardini, Andrea, Celsa, Ciro, Galati, Giovanni, Gambato, Martina, Crocetti, Laura, Renzulli, Matteo, Giannini, Edoardo G, Farinati, Fabio, Trevisani, Franco, Cillo, Umberto, Miele, Luca, HCC Special Interest Group of the Italian Association for the Study of the, Liver, Ponziani, Francesca Romana (ORCID:0000-0002-5924-6238), Miele, Luca (ORCID:0000-0003-3464-0068), HCC Special Interest Group of the Italian Association for the Study of the Liver, Vitale, Alessandro, Cabibbo, Giuseppe, Iavarone, Massimo, Viganò, Luca, Pinato, David J, Ponziani, Francesca Romana, Lai, Quirino, Casadei-Gardini, Andrea, Celsa, Ciro, Galati, Giovanni, Gambato, Martina, Crocetti, Laura, Renzulli, Matteo, Giannini, Edoardo G, Farinati, Fabio, Trevisani, Franco, Cillo, Umberto, Miele, Luca, HCC Special Interest Group of the Italian Association for the Study of the, Liver, Ponziani, Francesca Romana (ORCID:0000-0002-5924-6238), Miele, Luca (ORCID:0000-0003-3464-0068), and HCC Special Interest Group of the Italian Association for the Study of the Liver

Abstract

Advances in the surgical and systemic therapeutic landscape of hepatocellular carcinoma have increased the complexity of patient management. A dynamic adaptation of the available staging-based algorithms is required to allow flexible therapeutic allocation. In particular, real-world hepatocellular carcinoma management increasingly relies on factors independent of oncological staging, including patients' frailty, comorbid burden, critical tumour location, multiple liver functional parameters, and specific technical contraindications impacting the delivery of treatment and resource availability. In this Policy Review we critically appraise how treatment allocation strictly based on pretreatment staging features has shifted towards a more personalised treatment approach, in which expert tumour boards assume a central role. We propose an evidence-based framework for hepatocellular carcinoma treatment based on the novel concept of multiparametric therapeutic hierarchy, in which different therapeutic options are ordered according to their survival benefit (ie, from surgery to systemic therapy). Moreover, we introduce the concept of converse therapeutic hierarchy, in which therapies are ordered according to their conversion abilities or adjuvant abilities (ie, from systemic therapy to surgery).

Published
2023

47. Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma

Author

Cucchetti, Alessandro, Giannini, Edoardo G., Mosconi, Cristina, Plaz Torres, Maria Corina, Pieri, Giulia, Farinati, Fabio, Rapaccini, Gian Ludovico, Di Marco, Maria, Caturelli, Eugenio, Sacco, Rodolfo, Cabibbo, Giuseppe, Campani, Claudia, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati‐Baroni, Gianluca, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Sansone, Vito, Zoli, Marco, Azzaroli, Francesco, Trevisani, Franco, Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Rampoldi, Davide, Reggidori, Nicola, Santi, Valentina, Stefanini, Benedetta, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Tovoli, Francesco, Magalotti, Donatella, Dajti, Elton, Marasco, Giovanni, Ravaioli, Federico, Cappelli, Alberta, Golfieri, Rita, Renzulli, Matteo, Pelizzaro, Filippo, Penzo, Barbara, Marina Cela, Ester, Facciorusso, Antonio, Cacciato, Valentina, Casagrande, Edoardo, de Matthaeis, Nicoletta, Allegrini, Gloria, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Dell'Isola, Serena, Biasini, Elisabetta, Olivani, Andrea, Inno, Alessandro, Marchetti, Fabiana, Celsa, Ciro, Grova, Mauro, Stornello, Caterina, Busacca, Anita, Cammà, Calogero, Maria Rizzo, Giacomo Emanuele, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Napoli, Lucia, Bevilacqua, Vittoria, Berardinelli, Dante, Borghi, Alberto, Gardini, Andrea Casadei, Conti, Fabio, Dall'Aglio, Anna Chiara, Ercolani, Giorgio, Marra, Fabio, Di Bonaventura, Chiara, Gitto, Stefano, Adotti, Valentina, Coccoli, Pietro, Malerba, Antonio, Capasso, Mario, Morisco, Filomena, Oliveri, Filippo, Romagnoli, Veronica, Cucchetti, Alessandro, Giannini, Edoardo G., Mosconi, Cristina, Plaz Torres, Maria Corina, Pieri, Giulia, Farinati, Fabio, Rapaccini, Gian Ludovico, Di Marco, Maria, Caturelli, Eugenio, Sacco, Rodolfo, Cabibbo, Giuseppe, Campani, Claudia, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati‐Baroni, Gianluca, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Sansone, Vito, Zoli, Marco, Azzaroli, Francesco, Trevisani, Franco, Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Rampoldi, Davide, Reggidori, Nicola, Santi, Valentina, Stefanini, Benedetta, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Tovoli, Francesco, Magalotti, Donatella, Dajti, Elton, Marasco, Giovanni, Ravaioli, Federico, Cappelli, Alberta, Golfieri, Rita, Renzulli, Matteo, Pelizzaro, Filippo, Penzo, Barbara, Marina Cela, Ester, Facciorusso, Antonio, Cacciato, Valentina, Casagrande, Edoardo, de Matthaeis, Nicoletta, Allegrini, Gloria, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Dell'Isola, Serena, Biasini, Elisabetta, Olivani, Andrea, Inno, Alessandro, Marchetti, Fabiana, Celsa, Ciro, Grova, Mauro, Stornello, Caterina, Busacca, Anita, Cammà, Calogero, Maria Rizzo, Giacomo Emanuele, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Napoli, Lucia, Bevilacqua, Vittoria, Berardinelli, Dante, Borghi, Alberto, Gardini, Andrea Casadei, Conti, Fabio, Dall'Aglio, Anna Chiara, Ercolani, Giorgio, Marra, Fabio, Di Bonaventura, Chiara, Gitto, Stefano, Adotti, Valentina, Coccoli, Pietro, Malerba, Antonio, Capasso, Mario, Morisco, Filomena, Oliveri, Filippo, and Romagnoli, Veronica

Subjects
Liver Cancer, Pre-TACE-Predict model, medicine.medical_specialty, business.industry, Trans-arterial chemoembolization, Pharmaceutical Science, hepatocellular carcinoma, medicine.disease, Gastroenterology, Complementary and alternative medicine, Internal medicine, Hepatocellular carcinoma, medicine, Pharmacology (medical), Trans arterial chemoembolization, business
Abstract

Background & Aims The Pre-TACE-Predict model was devised to assess prognosis of patients treated with trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). However, before entering clinical practice, a model should demonstrate that it performs a useful role. Methods We performed an independent external validation of the Pre-TACE model in a cohort that differs in setting and time period from the one that generated the original model. Data from 826 patients treated with TACE for naïve HCC (2008-2018) were used to assess calibration and discrimination of the Pre-TACE-Predict model. Results The four risk-categories identified by the Pre-TACE-Predict model had gradient monotonicity, with median survivals of 52.0, 36.2, 29.9, and 14.1 months respectively. However, predicted survivals systematically underestimated observed survivals (R2: 0.667). A recalibration was adopted maintaining fixed the prognostic index and modifying the baseline survival function. This resulted in an almost perfect calibration (R2: 0.995) in all the four risk categories. Cox regressions showed that aetiology and macrovascular invasion, included in the Pre-TACE-Predict model, had no prognostic impact in the present study population, and that coefficients for tumour size and multiplicity were overestimated. The c-index was similar to that of the m-HAP-III, but higher than those of HAP, m-HAP-II and the six-and-twelve models. Conclusions The recalibration of Pre-TACE-Predict model improved the estimation of survival probabilities of HCC patients treated with TACE. The highest discriminatory ability of the Pre-TACE-model in comparison to other available models, together with risk stratification and recalibration, makes it the best prognostic tool currently available for these patients.

Published
2021

48. Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria

Author

Ravaioli, Matteo, Odaldi, Federica, Cucchetti, Alessandro, Trevisani, Franco, Piscaglia, Fabio, De Pace, Vanessa, Bertuzzo, Valentina Rosa, Neri, Flavia, Golfieri, Rita, Cappelli, Alberta, D’Errico, Antonietta, Cescon, Matteo, Del Gaudio, Massimo, Fallani, Guido, Siniscalchi, Antonio, Morelli, Maria Cristina, Ciccarese, Francesca, Di Marco, Maria, Farinati, Fabio, Giannini, Edoardo Giovanni, and Pinna, Antonio Daniele

Published
2019
Full Text
View/download PDF

49. Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma

Author

Ielasi, Luca, primary, Tovoli, Francesco, additional, Tonnini, Matteo, additional, Stefanini, Bernardo, additional, Tortora, Raffaella, additional, Magini, Giulia, additional, Sacco, Rodolfo, additional, Pressiani, Tiziana, additional, Trevisani, Franco, additional, Garajová, Ingrid, additional, Piscaglia, Fabio, additional, and Granito, Alessandro, additional

Published
2023
Full Text
View/download PDF

50. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study

Author

Vitale, Alessandro, Burra, Patrizia, Frigo, Anna Chiara, Trevisani, Franco, Farinati, Fabio, Spolverato, Gaya, Volk, Michael, Giannini, Edoardo G., Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Cabibbo, Giuseppe, Felder, Martina, Gasbarrini, Antonio, Sacco, Rodolfo, Foschi, Francesco Giuseppe, Missale, Gabriele, Morisco, Filomena, Svegliati Baroni, Gianluca, Virdone, Roberto, and Cillo, Umberto

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results